(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) slid by a staggering 20.46% in 5 sessions from $11.87 at -20.46, to $9.44 at 11:28 EST on Wednesday, after four sequential sessions in a row of losses. NASDAQ is jumping 0.12% to $11,874.33, after two sequential sessions in a row of gains.
Viking Therapeutics’s last close was $9.38, 21.7% below its 52-week high of $11.98.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.67%.
Moving Average
Viking Therapeutics’s value is below its 50-day moving average of $9.80 and way higher than its 200-day moving average of $5.08.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.90%, a negative 0.39%, and a positive 3.34%.
Viking Therapeutics’s highest amplitude of average volatility was 6.94% (last week), 3.52% (last month), and 3.34% (last quarter).
Volume
Today’s last reported volume for Viking Therapeutics is 1334970 which is 41.66% below its average volume of 2285380.
More news about Viking Therapeutics (VKTX).
